Table 3 Concomitant Chemotherapy
Study | Concomitant chemotherapy No.(%) | Locoregional control | Overall survival |
|---|---|---|---|
Yalin, 2002 | UC, SCC: COP or PCV AC: PCV 114 (100) | NR | UC: 32%, SCC: 33% AC: 38% at 5 years |
Boscolo-Rizzo, 2006 | Platinum based 9 (11) | NR | 25% at 5 years, 19% at 10 years |
Beldi, 2007 | Platinum based 21 (19) | disease free survival 27% at 5 years | 41% at 5 years |
Corry, 2008 | Platinum based 102 (100) | neck failure ultimately 9% | 60% at 3 years |
Ligey, 2009 | Platinum based 43 (45) | neck control 66% at 5 years | 24% at 5 years |
Lu, 2009 | Platinum based 14 (23) | neck control 66% at 5 years | 69% at 5 years |
Chen, 2011 | Platinum based 32 (53) | locoregional control 89% at 2 years | 89% at 2 years |
Wallace, 2011 | Ctx (drugs NR) 13 (7) | mucosal control 92% and neck control 81% at 5 years | 52% at 5 years |
Fakhrian, 2012 | Ctx 19 (29) Cis based 10, 5-FU + MMC 9 | locoregional lymph node recurrence, ultimately 14% | 48% at 5 years |
Tribius, 2012 | Cis 38 (60) | neck recurrence 25%, median 7 months | 76% at 2 years |
Demiroz, 2013 | Ctx, 4 regimes 25 (61) | LRFS: dRT: 75% ND + RT: 76% at 4 years | definitve RT: 85% ND + RT: 85% at 4 years |
Straetmans, 2014 | Carbo 8 (16) | neck recurrence ultimately 18% | 55% at 5 years |